Glytec Recognized Among TIME’s Top HealthTech Companies
In a significant achievement for the healthcare technology arena,
Glytec, a prominent player in inpatient insulin management and metabolic care, has earned a coveted spot on
TIME Magazine's list of the
World's Top HealthTech Companies for 2026. This recognition speaks volumes about Glytec's commitment to leveraging digital innovations to improve healthcare delivery and access.
TIME, in collaboration with
Statista, assessed various healthcare companies worldwide, considering factors such as financial performance, reputation, and online engagement. Glytec's inclusion in this prestigious ranking underscores its unwavering dedication to enhancing patient care through advanced clinical solutions.
A Legacy of Excellence
Glytec boasts over two decades of expertise in glycemic management, constantly expanding its clinical intelligence offerings for high-cost, high-acuity medical conditions. At the core of this initiative is its flagship
GlytecOne™ system, which integrates clinical solutions designed to optimize healthcare outcomes across various metrics, including clinical, operational, and financial performance.
The
GlytecOne™ platform features
Glucommander®, Glytec’s FDA-cleared glycemic management system that has set the industry standard for insulin dosing and inpatient diabetes management for 20 years. This tool empowers leading healthcare providers across the nation by delivering precise insulin dosing recommendations tailored to the needs of patients battling diabetes and stress-induced hyperglycemia.
Revolutionizing Metabolic Care
The clinical solutions provided by
GlytecOne™ adopt an integrated methodology aimed at advancing metabolic care. By synergizing clinical intelligence with actual clinical decisions and workflows, Glytec addresses critical areas where glucose levels are vital indicators, such as diabetes management, sepsis, heart failure, cardiac surgery, and pneumonia. Understanding glucose as a unifying clinical signal opens up innovative paths for developing a new care category —
Metabolic Intelligence.
By converting glucose-related data into actionable insights across various medical conditions, Glytec facilitates a more interconnected and intelligent approach to patient care. Through its sophisticated combination of condition-specific knowledge, workflow integration, and predictive analytics, Glytec enables healthcare teams to identify at-risk patients earlier, minimize discrepancies in care, and alleviate the cognitive load on nursing staff.
A Commitment to Improving Patient Care
Patrick Cua, the CEO of Glytec, expressed pride in the acknowledgment from
TIME, stating, “This recognition marks a proud moment for our team and reflects the trust that hospitals place in Glytec every day. We build upon two decades of expertise in insulin management to help care teams recognize risks earlier and act with increased confidence across a wider range of patient conditions.” He further emphasized their mission: “We aim to assist clinicians in delivering better care while easing their workload.”
About Glytec
Glytec, LLC is a trailblazer in healthcare technology and clinical intelligence. Its mission centers around enhancing treatment outcomes for high-risk patient populations by leveraging advanced resources and expertise in glycemic management. The company provides tools that equip healthcare institutions with nearly real-time insights and support for clinical decisions across critical health concerns, ranging from diabetes to severe cases like sepsis, heart failures, and more. The company’s commitment is reflected in its aim to bolster the effectiveness of hospitals and health systems, ultimately advancing the quality of patient care and operational success. For further details, visit
Glytec's official website.